Parexel: 2016 prescribing decisions to be driven by clinical and real-world data

By Staff Reporter

- Last updated on GMT

Image: iStock/mpalis
Image: iStock/mpalis

Related tags: Pharmaceutical industry

In 2016 clinical trial and real-world data will become increasingly important in the decision to prescribe medicine, Parexel President and COO Mark Goldberg told

The concept of payers utilising clinical and outcomes data is not a new one. However, with escalating pressures on national healthcare budgets in today's economy - and as a result of an ever ageing population - the need to prove real-world efficacy is arguably more apparent than ever.

Merely demonstrating safety and efficacy and getting approval in today’s pharmaceutical landscape is no longer enough to launch a product successfully and ensure return on investment, Goldberg said.

Therefore this year, Goldberg predicted there will be a major trend for using real-world proof of improved outcomes to drive prescribing behaviours. There will also be bigger emphasis on integrating commercial insights into clinical data from an early stage to ensure not only regulatory approval, but also commercial success, he said.

For CROs like Parexel and its sponsors, key study focuses will therefore include interventional and observational trials, managed access programs, real-world evidence studies and pharmacovigilance studies.

Parexel has already seen increased outsourcing in regulatory affairs, market access, and pharmacovigilance in recent years, Goldberg noted.

Other CROs which have shown growing interest in real-world data services in recent months includes Quintiles which formed an alliance with IMS Health for access to such information, this publication reported​ in October.

In June, PPD also partnered insurance company Anthem in a bid to offer real-world outcomes data outside of the clinical trial spectrum.

Parexel also launched its ACCESS marketing and commercial service offering in November, which includes commercialisation and pharmacovigilance aspects.

As for Parexel's new year resolutions, the company will continue to seek M&A opportunities which are complementary to its existing portfolio, he noted.  It also expects to see continued demand in complex global studies.

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more